Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus

This study has been completed.
Information provided by:
Massachusetts General Hospital Identifier:
First received: November 21, 2006
Last updated: November 22, 2006
Last verified: November 2006

We hypothesize that atorvastatin will decrease HCV viral load in patients taking the medication.

Cholesterol is needed for HCV virion production. Cell culture studies have shown that atorvastatin (an HMG-CoA reductase inhibitor) decreases HCV viral replication. As atorvastatin has been proven to decrease heart attack and stroke in patients with high cholesterol, this medication is indicated for the treatment of elevated cholesterol in at risk individuals. Therefore we propose to study the effect atorvastatin has on the viral load of patients initiated on atorvastatin therapy for their elevated cholesterol.

Condition Intervention Phase
Hepatitis C
Drug: 20 mg of atorvastatin daily
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Paired comparison of pretreatment viral load to post-treatment 12 week viral load

Secondary Outcome Measures:
  • Paired comparison of pretreatment viral load to post-treatment 4 week viral load

Estimated Enrollment: 10
Study Start Date: February 2006
Estimated Study Completion Date: July 2006
Detailed Description:

Men and women ages 30 to 80 infected with HCV viremia whose physician has determined need cholesterol lowering medication will be recruited by the study investigators from Massachusetts General Hospital.

The study investigators will approach the potential subject after the referring doctor has ascertained that the potential subject is interested in meeting with the investigator.

Each subject who consents will undergo phlebotomy of 10 cc of blood three times. Once prior to the initiation of atorvastatin to measure the patients viral load. In addition, patients will undergo phlebotomy 4 and 12 weeks after the initiation of atorvastatin. The week 12 phlebotomy is required in all patients started on atorvastatin to monitor for side effects. Therefore patients who enroll in this study will undergo one additional phlebotomy. As part of our study an extra 10 cc of blood will be taken at these times to measure the patients HCV viral load.


Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with chronic HCV.
  • Patients who need treatment for their elevated cholesterol:

    • Total cholesterol >240 or
    • LDL >160 without cardiac risk factors or
    • LDL >130 with two cardiac risk factors (hypertension, smoker, family history of heart attach, or HDL <40 for men or <50 for women) or
    • LDL >100 with diabetes or known coronary artery disease

Exclusion Criteria:

  • Impaired mental ability preventing a subject from understanding the protocol or from completing the entire study.
  • HCC
  • A history of an adverse reaction to any HMG CoA reductase inhibitor.
  • Patients who are on HCV treatment, who plan to initiate HCV treatment within 3 months, or who discontinued HCV treatment within the last 3 months.
  • Patients whose aminotransferases are > 5 times the upper limit of normal.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00403533

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Raymond T Chung, MD Massachusetts General Hospital
  More Information

Publications: Identifier: NCT00403533     History of Changes
Other Study ID Numbers: 2006-P-000138/1  AASLD advanced hepato. grant 
Study First Received: November 21, 2006
Last Updated: November 22, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Hepatitis C
viral load
antiviral therapy

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Antiviral Agents
Atorvastatin Calcium
Anti-Infective Agents
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 24, 2016